Codex DNA extends the application of proprietary error correction technology

SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) — Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated synthetic biology benchtop systems, today announced the commercial launch of error-correcting library kits BioXp ® that allow researchers to automate the synthesis of DNA variant libraries on the award-winning BioXp automated synthetic biology workstation ®.

“This addition to the BioXp solutions® demonstrates a new, expanded application of Codex DNA’s proprietary 2-step error correction technology. We believe that the ability to automate the synthesis of DNA variant libraries on the BioXp system®that can contain up to 64 million variants per well, and with 2x higher fidelity than before, will enable scientists, in applications such as antibody-based treatments, enzyme engineering and cell-based therapies both gene and cellular, including precision medicine, to optimize their workflows and engineer the specificity, binding and activity of mRNAs and proteins with increased speed and accuracy,” said Todd R. Nelson, PhD, CEO of Codex DNA.

The BioXp system® builds customer-specific high-fidelity sequence variant DNA readout, site saturation, and combinatorial libraries immediately at the push of a button. Error-corrected libraries are generated from gene synthesis, assembly, Codex DNA’s proprietary error-correction technology and amplification to produce purified sequence variant DNA libraries, which are ready to be used in downstream research applications such as cloning, screening or selection. This solution enables researchers to build DNA libraries of up to 64 million variants per well, with 2x higher fidelity than non-error-corrected libraries, without compromising expected amino acid sequence diversity.

“By providing a solution that enables library synthesis with immediate error correction, regardless of sequence complexity, we are empowering researchers to expand and accelerate their screening and discovery workflows and achieve more quickly into cutting-edge discovery applications,” added Todd R. Nelson.

About Codex DNA
Codex DNA empowers scientists to create new synthetic biology-based solutions to address humanity’s greatest challenges. As the inventor of the standard Gibson Assembly method® and the first automated commercial benchtop DNA and mRNA synthesis system, Codex DNA enables the rapid, accurate and reproducible writing of DNA and mRNA for many downstream markets. The award-winning BioXp system® consolidates, automates and optimizes the entire synthesis, cloning and amplification workflow. It thus enables DNA and RNA to be synthesized virtually error-free on a large scale, in days and hours instead of weeks or months. Scientists around the world are using this technology in their own labs to accelerate the design-build-test paradigm for new, high-value products for precision medicine, biologic drug discovery, vaccine and therapy development, genome editing and cell and gene therapy. Codex DNA is a public company based in San Diego. For further information, please visit the website codexdna.com.

Codex DNA, the Codex DNA logo, Gibson Assembly, BioXp and RapidAMP are trademarks of Codex DNA Inc.

Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Codex’s beliefs and assumptions. DNA and on the information currently available at the date of publication of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that could cause Codex DNA’s actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. . These and other risks are fully described in Codex DNA’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Codex DNA subsequently files with the SEC from time to time. Except to the extent required by law, Codex DNA disclaims any obligation to update these statements to reflect events that occur or circumstances that exist after the date on which they were presented.

Media contact:

Charlie Schmidt

Senior Marketing Director

[email protected]


Print Friendly, PDF & Email

Leave a Comment